• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

Bristol-Myers Squibb

Gastric cancer.
Posted inOncology, Regulatory

Opdivo and Keytruda: First-line Immunotherapy for Gastric Cancer and Esophageal Cancer

April 20, 2021September 8, 2022

Nivolumab or pembrolizumab should be added to standard chemotherapy to prolong the life of patients with gastric, esophageal, and gastroesophageal junction cancers.

Lungs.
Posted inClinical Trials, In the Pipeline, Oncology, Regulatory

Small Cell Lung Cancer: Let Immunotherapy Help!

April 3, 2021September 8, 2022

A deadly disease and modern pharmacological attempts to treat it.

Multiple sclerosis.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Mayzent: New Drug for Treatment of Secondary Progressive Multiple Sclerosis

April 1, 2021September 8, 2022

Siponimod released by Novartis is an improved version of Gilenya.

Posts navigation

Newer posts 1 2
BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News